Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 25Gastrointestinal 8Head & Neck 4Tumor-Agnostic 2Other solid neoplasm 2Gynecologic 1CNS 1Breast 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × amivantamab × Tumor-Agnostic × Clear all
NCT05117931 2026-02-17

A Study of Amivantamab in People With Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03767075 2024-04-25

BoB

Vall d'Hebron Institute of Oncology

Phase 2 Recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡